Electron microscopy analysis of early localization of cisplatin in ovarian carcinoma cells

被引:28
作者
Beretta, GL [1 ]
Righetti, SC [1 ]
Lombardi, L [1 ]
Zunino, F [1 ]
Perego, P [1 ]
机构
[1] Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy
关键词
cisplatin; localization; ovarian carcinoma cells;
D O I
10.1080/01913120290104610
中图分类号
TH742 [显微镜];
学科分类号
摘要
Taking advantage of the electron-dense nature of platinum, in this study the authors used an electron microscopy approach to investigate the cellular localization of cisplatin in an ovarian carcinoma cell line. Platinum spots were detected in contact with the plasma membrane and the nuclear envelope as well as in the cytoplasm and nuclear matrices. Contact with the plasma membrane was through a single blunt contact or spanning through the membrane. No sequestration in intracellular vescicles was observed, thereby supporting that phagocytosis and receptor-mediated endocytosis were not occurring. A molecular analysis indicated lack of expression of aquaporin 9, thus excluding its involvement in the membrane translocation of cisplatin. The present data suggest that cisplatin rapidly accumulates in the cell through endocytosis-independent membrane translocation and are consistent with passive diffusion.
引用
收藏
页码:331 / 334
页数:4
相关论文
共 19 条
[1]  
Andrews P A, 1994, Cancer Treat Res, V73, P217
[2]  
Andrews PA, 2000, CANC DRUG DISC DEV, V7, P89
[3]  
ANDREWS PA, 1988, CANCER RES, V48, P68
[4]  
BASU A, 1990, J BIOL CHEM, V265, P8451
[5]   CELLULAR ACCUMULATION OF THE ANTICANCER AGENT CISPLATIN - A REVIEW [J].
GATELY, DP ;
HOWELL, SB .
BRITISH JOURNAL OF CANCER, 1993, 67 (06) :1171-1176
[6]  
GHADIALLY FN, 1981, J SUBMICR CYTOL PATH, V13, P223
[7]  
GHADIALLY FN, 1981, VIRCHOWS ARCH B, V35, P123
[8]   RESTORATIVE EFFECTS OF CALMODULIN ANTAGONISTS ON REDUCED CISPLATIN UPTAKE BY CISPLATIN-RESISTANT HUMAN OVARIAN-CANCER CELLS [J].
KIKUCHI, Y ;
IWANO, I ;
MIYAUCHI, M ;
SASA, H ;
NAGATA, I ;
KUKI, E .
GYNECOLOGIC ONCOLOGY, 1990, 39 (02) :199-203
[9]   Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance [J].
Lanzi, C ;
Perego, P ;
Supino, R ;
Romanelli, S ;
Pensa, T ;
Carenini, N ;
Viano, I ;
Colangelo, D ;
Leone, R ;
Apostoli, P ;
Cassinelli, G ;
Gambetta, RA ;
Zunino, F .
BIOCHEMICAL PHARMACOLOGY, 1998, 55 (08) :1247-1254
[10]  
LEROY AF, 1979, CANCER TREAT REP, V63, P59